Smith & Nephew plc (ADR) Receives Consensus Recommendation of “Buy” from Brokerages (NYSE:SNN)
Smith & Nephew plc (ADR) (NYSE:SNN) has been given an average rating of “Buy” by the sixteen analysts that are presently covering the stock, Analyst RN reports. One investment analyst has rated the stock with a sell rating, six have given a hold rating and nine have assigned a buy rating to the company. The average 12-month target price among brokers that have updated their coverage on the stock in the last year is $80.00.
Shares of Smith & Nephew plc (NYSE:SNN) opened at 73.26 on Monday. Smith & Nephew plc has a 52 week low of $54.73 and a 52 week high of $80.42. The stock has a 50-day moving average of $76.54 and a 200-day moving average of $71.01. The company has a market cap of $13.075 billion and a P/E ratio of 23.86.
Smith & Nephew plc (ADR) (NYSE:SNN) last announced its earnings results on Thursday, February 6th. The company reported $1.16 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.13 by $0.03. On average, analysts predict that Smith & Nephew plc will post $4.13 earnings per share for the current fiscal year.
SNN has been the subject of a number of recent research reports. Analysts at Numis Securities Ltd downgraded shares of Smith & Nephew plc (ADR) to a “hold” rating in a research note on Thursday, April 3rd. Separately, analysts at Investec upgraded shares of Smith & Nephew plc (ADR) to a “buy” rating in a research note on Friday, March 28th. Finally, analysts at Summer Street raised their price target on shares of Smith & Nephew plc (ADR) from $80.00 to $83.00 in a research note on Monday, February 24th. They now have a “buy” rating on the stock.
Smith & Nephew plc is a global medical devices business operating in the markets for orthopaedic reconstruction and trauma, endoscopy (NYSE:SNN) and advanced wound management.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.